Safety Reading Notes

Read safety context beside the research guide.

The CBGA source set should still be read with safety context in mind. Mechanistic or preclinical evidence should not be converted into consumer instructions, and product identity can change how closely a source applies. PMID 36257598

PubMed For Dummies Article

CBGA Evidence Review: the long-form source walk-through

Quick read
  • CBGA currently has 45 source-backed evidence row(s), so this page should be read as a research guide rather than a single conclusion. PMID 36257598
  • The evidence classes most visible in the row language are insufficient (21), mechanistic or pharmacological (19), preliminary human (3), and preclinical (2). PMID 35910331
  • The study-design language most visible in the row language is Narrative or expert review (12), Animal study (9), Cellular or in vitro study (6), and other mapped categories (3). PMID 41545891
  • The repeated topics are receptor, target, or pharmacology mechanisms (12), Skin and inflammatory dermatology (4), nausea-related or inflammation-related outcomes (3), safety, tolerability, adverse-event, impairment, toxicity, or formulation-spe... (3), and other mapped categories (23), which tells the reader where to start opening PubMed and DOI links. PMID 28117322

Start with the research question

CBGA is built from 45 source-backed evidence row(s) and 33 research source(s). The current evidence classes read as insufficient (21), mechanistic or pharmacological (19), preliminary human (3), and preclinical (2), and the study-design language most often reads as Narrative or expert review (12), Animal study (9), Cellular or in vitro study (6), and other mapped categories (3). PMID 36257598

The row-level question is not simply whether CBGA is "good" or "bad." The useful question is what each row studied, what evidence class it received, and whether the source is close to the reader's actual question. The most repeated row topics are receptor, target, or pharmacology mechanisms (12), Skin and inflammatory dermatology (4), nausea-related or inflammation-related outcomes (3), safety, tolerability, adverse-event, impairment, toxicity, or formulation-spe... (3), and other mapped categories (23). PMID 37630401

Human evidence 2 rows

Rows involving human participants, patients, or clinical source language. These rows are closer to everyday reader questions, but still depend on population, dose, route, comparator, and endpoint. PMID 37083031

Preclinical evidence 2 rows

Animal, cellular, or model-based rows. These can explain why a topic is being studied, but they should not be read as human-health instructions. PMID 32401504

Mechanistic evidence 16 rows

Rows about receptors, enzymes, channels, metabolism, binding, signaling, or pharmacology. These explain plausibility without proving a consumer outcome. PMID 41822224

Limits and uncertainty 28 rows

Rows where safety, tolerability, risk, product limits, or insufficient evidence need to stay visible next to the rest of the article. PMID 37630401

The lane labels are not a quality score. They are a reading method: keep human evidence, preclinical evidence, mechanisms, and uncertainty in separate mental boxes before deciding what a source can actually support. PMID 38162115

Where this page has the most source density

The largest bucket surfaced for this page is receptor, target, or pharmacology mechanisms. That does not automatically mean the topic is settled; it means this is where the current source trail is densest. The next visible bucket is Skin and inflammatory dermatology, which gives readers another way to see what the literature repeatedly circles. PMID 36257598

Source density should be read with evidence posture. A bucket can contain many rows and still be limited if the studies are indirect, mixed, preclinical, product-specific, or mostly review-level. The paragraphs below name the buckets directly and keep each explanation connected to a source record. PMID 37630401

Bucket chapters: what the literature is circling

receptor, target, or pharmacology mechanisms

5 research sources 5 rows (201-287) Mechanistic research summary: insufficient (3), mechanistic or pharmacological (2)

CBGA appears in rows studying receptor, target, or pharmacology mechanisms. It currently draws from 5 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 36257598

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 36257598

  • Evidence row 201

    THC studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (outcome measure: receptor, target, or pharmacology mechanisms). PMID 36257598

  • Evidence row 287

    THC studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (outcome measure: receptor, target, or pharmacology mechanisms). PMID 35566314

Skin and inflammatory dermatology

4 research sources 4 rows (702-717) Developed but mixed human research summary: insufficient (1), mechanistic or pharmacological (2), preliminary human (1)

CBGA appears in rows studying Skin and inflammatory dermatology. It currently draws from 4 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 37630401

Read this bucket as closer to a real-world question, then check the study population, dose, product, comparator, and endpoint before generalizing beyond the source. PMID 37630401

  • Evidence row 702

    CBC studied for Skin and inflammatory dermatology; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: skin, dermatology, antim... PMID 37630401

  • Evidence row 717

    CBC studied for Skin and inflammatory dermatology; evidence class: preliminary human (population or model: Human participants or patients mentioned; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory out... PMID 41983582

Appetite and metabolic outcomes

3 research sources 3 rows (627-635) Developed but mixed human research summary: insufficient (1), preclinical (1), preliminary human (1)

CBGA appears in rows studying Appetite and metabolic outcomes. It currently draws from 3 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 36397993

Read this bucket as closer to a real-world question, then check the study population, dose, product, comparator, and endpoint before generalizing beyond the source. PMID 36397993

  • Evidence row 627

    CBG studied for Appetite and metabolic outcomes; evidence class: insufficient (study design: Narrative or expert review; outcome measure: appetite-related, weight, glucose, or metabolic outcomes). PMID 36397993

  • Evidence row 635

    CBG studied for Appetite and metabolic outcomes; evidence class: preclinical (outcome measure: appetite-related, weight, glucose, or metabolic outcomes). PMID 39192735

nausea-related or inflammation-related outcomes

3 research sources 3 rows (125-140) Mechanistic research summary: insufficient (2), mechanistic or pharmacological (1)

CBGA appears in rows studying nausea-related or inflammation-related outcomes. It currently draws from 3 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 41545891

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 41545891

  • Evidence row 125

    CBDA studied for nausea-related or inflammation-related outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome m... PMID 41545891

  • Evidence row 140

    CBDA studied for nausea-related or inflammation-related outcomes; evidence class: insufficient (outcome measure: nausea-related or inflammation-related outcomes). PMID 32401504

receptor, target, or pharmacology mechanisms

3 research sources 3 rows (279-281) Mechanistic and preclinical research summary: insufficient (1), mechanistic or pharmacological (1), preclinical (1)

CBGA appears in rows studying receptor, target, or pharmacology mechanisms. It currently draws from 3 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 34980287

Read this bucket as closer to a real-world question, then check the study population, dose, product, comparator, and endpoint before generalizing beyond the source. PMID 34980287

  • Evidence row 279

    CBD studied for receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharma... PMID 34980287

  • Evidence row 281

    CBD studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms). PMID 40006604

Pain-related outcomes

2 research sources 2 rows (68-70) Mapped evidence with interpretation limits: insufficient (2)

CBGA appears in rows studying Pain-related outcomes. It currently draws from 2 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 35910331

Read this bucket as an uncertainty marker. The source trail exists, but the current evidence posture is not strong enough for a broad plain-English conclusion. PMID 35910331

  • Evidence row 68

    CBG studied for Pain-related outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes). PMID 35910331

  • Evidence row 70

    CBG studied for Pain-related outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: pain-related outcom... PMID 41545891

Receptor, target, metabolic, and pharmacology mechanisms

2 research sources 2 rows (765-780) Mechanistic research summary: mechanistic or pharmacological (2)

CBGA appears in rows about Receptor, target, metabolic, and pharmacology mechanisms mechanisms. It currently draws from 2 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 21175579

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 21175579

  • Evidence row 765

    THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure:... PMID 21175579

  • Evidence row 780

    THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target,... PMID 21726418

receptor, target, or pharmacology mechanisms

2 research sources 2 rows (283-284) Mapped evidence with interpretation limits: insufficient (2)

CBGA appears in rows studying receptor, target, or pharmacology mechanisms. It currently draws from 2 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 39808700

Read this bucket as an uncertainty marker. The source trail exists, but the current evidence posture is not strong enough for a broad plain-English conclusion. PMID 39808700

  • Evidence row 283

    CBC studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (outcome measure: receptor, target, or pharmacology mechanisms). PMID 39808700

  • Evidence row 284

    CBC studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target,... PMID 35306000

Human evidence, mechanisms, and safety are different lanes

This page currently separates human evidence (2 row(s)), mechanistic evidence (16 row(s)), and safety/tolerability context (7 row(s)). That separation is the heart of the site. Mechanistic evidence can make a topic biologically interesting, but it should not silently become a human outcome. PMID 36257598

Human evidence still depends on population, dose, route, duration, product identity, and endpoint. Safety rows belong in the same reading path as benefit-oriented rows because formulation, co-exposures, prescription medications, impairment context, and higher-risk populations can change how close a source is to a reader's question. PMID 37630401

What this does and does not mean

  • It means the page has a traceable source trail. It does not mean every bucket has the same clinical strength. PMID 34980287
  • It means mechanisms, animal models, human studies, safety rows, and insufficient-evidence rows are being kept visible as separate evidence types. PMID 34384142
  • It does not turn a preclinical mechanism into a consumer recommendation, and it does not treat one product, dose, route, or population as interchangeable with another. PMID 40006604

How to use the source table

The source-backed evidence table below is the audit trail. Each row keeps a public sentence connected to a source record when a PubMed ID or DOI is available. If a sentence feels important, the reader should be able to click through, inspect the study type, and decide whether the source is close to the question they care about. PMID 36257598

This is why the public page is intentionally layered. The top gives the reader a fast orientation. The bucket table groups repeated rows into readable topics. The article body explains the buckets using the actual evidence-row language. The source notes below walk through every evidence row before the source table repeats the technical trace. PMID 37630401

Source-reading checklist for CBGA

  1. Open the linked PubMed or DOI record. PMID 32824356
  2. Check whether the source studied humans, animals, cells, chemistry, pharmacology, product testing, or a review of prior literature. PMID 39808700
  3. Compare the source product, dose, route, population, and endpoint to the question being asked. PMID 35306000
  4. Look for safety, tolerability, drug-interaction, impairment, pregnancy, pediatric, psychiatric, cardiovascular, and product-quality context before treating the bucket as settled. PMID 37708768
  5. Return to the evidence table when the article summary sounds too broad; the row is the audit unit. PMID 39013926

Source Notes

CBGA source-by-source reading notes

These notes pull every evidence row on this page into the readable article body before the source table repeats the audit trail. Each note keeps the row language beside the PubMed or DOI link when available.

  1. Evidence row 68

    CBG studied for Pain-related outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes). PMID 35910331

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Acidic Cannabinoids Suppress Proinflammatory Cytokine Release by Blocking Store-operated Calcium Entry.
  2. Evidence row 70

    CBG studied for Pain-related outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes). PMID 41545891

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Therapeutic potential of acidic cannabinoids: an update.
  3. Evidence row 71

    CBC studied for Inflammation-related outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: inflammation-related or pain-related outcomes). PMID 41545891

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Therapeutic potential of acidic cannabinoids: an update.
  4. Evidence row 92

    THCA studied for THCA-specific safety, effect, or mechanism claims; evidence class: insufficient (outcome measure: safety, effect, or mechanism claims). PMID 28117322

    Evidence class: insufficient. Source: Quality Control of Traditional Cannabis Tinctures: Pattern, Markers, and Stability.
  5. Evidence row 125

    CBDA studied for nausea-related or inflammation-related outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: nausea-related or inflammation-related outcomes). PMID 41545891

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Therapeutic potential of acidic cannabinoids: an update.
  6. Evidence row 137

    CBDA studied for nausea-related or inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: nausea-related or inflammation-related outcomes). PMID 37083031

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Antiviral activities of hemp cannabinoids.
  7. Evidence row 140

    CBDA studied for nausea-related or inflammation-related outcomes; evidence class: insufficient (outcome measure: nausea-related or inflammation-related outcomes). PMID 32401504

    Evidence class: insufficient. Source: Raman-Based Differentiation of Hemp, Cannabidiol-Rich Hemp, and Cannabis.
  8. Evidence row 165

    CBDA studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns). PMID 41822224

    Evidence class: mechanistic or pharmacological; Study design: Human clinical study. Source: Physiological effect and pharmacokinetic evaluation of combined oral administration of cannabidiolic acid and cannabigerolic acid in dogs.
  9. Evidence row 168

    CBG studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns). PMID 37630401

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Therapeutic Potential of Minor Cannabinoids in Dermatological Diseases-A Synthetic Review.
  10. Evidence row 201

    THC studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (outcome measure: receptor, target, or pharmacology mechanisms). PMID 36257598

    Evidence class: insufficient. Source: Development and Validation of a GC-FID Method for the Quantitation of 20 Different Acidic and Neutral Cannabinoids.
  11. Evidence row 277

    THC studied for receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 37083031

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Antiviral activities of hemp cannabinoids.
  12. Evidence row 278

    THC studied for receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 38162115

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabigerolic Acid (CBGA) Inhibits the TRPM7 Ion Channel Through its Kinase Domain.
  13. Evidence row 279

    CBD studied for receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 34980287

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Olivetolic acid, a cannabinoid precursor in Cannabis sativa, but not CBGA methyl ester exhibits a modest anticonvulsant effect in a mouse model of Dravet syndrome.
  14. Evidence row 280

    CBD studied for receptor, target, or pharmacology mechanisms; evidence class: preclinical (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 34384142

    Evidence class: preclinical; Study design: Animal study. Source: Cannabigerolic acid, a major biosynthetic precursor molecule in cannabis, exhibits divergent effects on seizures in mouse models of epilepsy.
  15. Evidence row 281

    CBD studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms). PMID 40006604

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacokinetics of Non-Psychotropic Phytocannabinoids.
  16. Evidence row 282

    CBCA studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 32824356

    Evidence class: insufficient; Study design: Cellular or in vitro study. Source: Rapid Antibacterial Activity of Cannabichromenic Acid against Methicillin-Resistant Staphylococcus aureus.
  17. Evidence row 283

    CBC studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (outcome measure: receptor, target, or pharmacology mechanisms). PMID 39808700

    Evidence class: insufficient. Source: Enhancing Cannabichromenic Acid Biosynthesis in Saccharomyces cerevisiae.
  18. Evidence row 284

    CBC studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 35306000

    Evidence class: insufficient; Study design: Cellular or in vitro study. Source: In vitro evaluation of the interaction of the cannabis constituents cannabichromene and cannabichromenic acid with ABCG2 and ABCB1 transporters.
  19. Evidence row 285

    THC studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (outcome measure: receptor, target, or pharmacology mechanisms). PMID 37708768

    Evidence class: insufficient. Source: Bidimensional heart-cut achiral-chiral liquid chromatography coupled to high-resolution mass spectrometry for the separation of the main chiral phytocannabinoids and enantiomerization studies of cannabichromene and cannabichromenic acid.
  20. Evidence row 286

    THCA studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (outcome measure: receptor, target, or pharmacology mechanisms). PMID 39013926

    Evidence class: insufficient. Source: Comparison of decarboxylation rates of acidic cannabinoids between secretory cavity contents and air-dried inflorescence extracts in Cannabis sativa cv. 'Cherry Wine'.
  21. Evidence row 287

    THC studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (outcome measure: receptor, target, or pharmacology mechanisms). PMID 35566314

    Evidence class: insufficient. Source: Direct Quantitation of Phytocannabinoids by One-Dimensional 1H qNMR and Two-Dimensional 1H-1H COSY qNMR in Complex Natural Mixtures.
  22. Evidence row 334

    THC studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: preliminary human (population or model: Human participants or patients mentioned; outcome measure: safety, risk, adverse-event, or formulation-specific concerns). PMID 31559335

    Evidence class: preliminary human. Source: Potency Analysis of Medical Marijuana Products from New York State.
  23. Evidence row 364

    THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms). PMID 21175579

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes.
  24. Evidence row 562

    CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: mechanistic or pharmacological (study design: Human clinical study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 35246858

    Evidence class: mechanistic or pharmacological; Study design: Human clinical study. Source: Single dose and chronic oral administration of cannabigerol and cannabigerolic acid-rich hemp extract in fed and fasted dogs: Physiological effect and pharmacokinetic evaluation.
  25. Evidence row 575

    CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 35887277

    Evidence class: insufficient; Study design: Narrative or expert review. Source: The Origin and Biomedical Relevance of Cannabigerol.
  26. Evidence row 627

    CBG studied for Appetite and metabolic outcomes; evidence class: insufficient (study design: Narrative or expert review; outcome measure: appetite-related, weight, glucose, or metabolic outcomes). PMID 36397993

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacological Aspects and Biological Effects of Cannabigerol and Its Synthetic Derivatives.
  27. Evidence row 629

    CBG studied for Appetite and metabolic outcomes; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: appetite-related, weight, glucose, or metabolic outcomes). PMID 34569849

    Evidence class: preliminary human; Study design: Human clinical study. Source: Survey of Patients Employing Cannabigerol-Predominant Cannabis Preparations: Perceived Medical Effects, Adverse Events, and Withdrawal Symptoms.
  28. Evidence row 635

    CBG studied for Appetite and metabolic outcomes; evidence class: preclinical (outcome measure: appetite-related, weight, glucose, or metabolic outcomes). PMID 39192735

    Evidence class: preclinical. Source: Ensiling conditions and changes of cannabinoid concentration in industrial hemp.
  29. Evidence row 640

    CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 37630401

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Therapeutic Potential of Minor Cannabinoids in Dermatological Diseases-A Synthetic Review.
  30. Evidence row 655

    CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: mechanistic or pharmacological (outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 41668212

    Evidence class: mechanistic or pharmacological. Source: Mapping the research landscape of minor cannabinoids: a bibliometric analysis of research trends and hotspots.
  31. Evidence row 661

    CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 40006604

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacokinetics of Non-Psychotropic Phytocannabinoids.
  32. Evidence row 682

    CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 35399958

    Evidence class: mechanistic or pharmacological. Source: In silico discovery of non-psychoactive scaffolds in Cannabis halting SARS-CoV-2 host entry and replication machinery.
  33. Evidence row 702

    CBC studied for Skin and inflammatory dermatology; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 37630401

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Therapeutic Potential of Minor Cannabinoids in Dermatological Diseases-A Synthetic Review.
  34. Evidence row 711

    CBC studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 35628241

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Effects of Rare Phytocannabinoids on the Endocannabinoid System of Human Keratinocytes.
  35. Evidence row 713

    CBC studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 36769042

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Rare Phytocannabinoids Exert Anti-Inflammatory Effects on Human Keratinocytes via the Endocannabinoid System and MAPK Signaling Pathway.
  36. Evidence row 717

    CBC studied for Skin and inflammatory dermatology; evidence class: preliminary human (population or model: Human participants or patients mentioned; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 41983582

    Evidence class: preliminary human. Source: Broad-spectrum bactericidal synergy of silver-cannabichromene-cannabigerol triple combinations against healthcare-associated pathogens.
  37. Evidence row 743

    THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns). PMID 37630401

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Therapeutic Potential of Minor Cannabinoids in Dermatological Diseases-A Synthetic Review.
  38. Evidence row 765

    THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 21175579

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes.
  39. Evidence row 780

    THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 21726418

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation.
  40. Evidence row 1008

    THC modulates TRPV3; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV3 channel activity, binding, signaling, dermatology-relevant mechanism, or pharmacology). PMID 21726418

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation.
  41. Evidence row 1019

    THC modulates TRPV4; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology). PMID 21726418

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation.
  42. Evidence row 1047

    CBD modulates TRPA1; evidence class: mechanistic or pharmacological (outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 38408345

    Evidence class: mechanistic or pharmacological. Source: Phytochemical Characterization and TRPA1/TRPM8 Modulation Profile of the Cannabigerol-Rich Cannabis sativa L. Chemotype IV.
  43. Evidence row 1050

    THC modulates TRPM8; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 21175579

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes.
  44. Evidence row 1058

    CBD modulates TRPM8; evidence class: mechanistic or pharmacological (outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 38408345

    Evidence class: mechanistic or pharmacological. Source: Phytochemical Characterization and TRPA1/TRPM8 Modulation Profile of the Cannabigerol-Rich Cannabis sativa L. Chemotype IV.
  45. Evidence row 1062

    CBG modulates TRPM8; evidence class: mechanistic or pharmacological (outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 30077611

    Evidence class: mechanistic or pharmacological. Source: Iodine-mediated cyclization of cannabigerol (CBG) expands the cannabinoid biological and chemical space.